Peter Savas

Alpelisib Monotherapy for PI3K-Altered Pretreated Advanced Breast Cancer A Phase II Study

Peter Savas, Louisa L Lo, Stephen J Luen, Elizabeth F Blackley, Jason Callahan, Kate Moodie, Courtney T van Geelen, Yi-An Ko, Chen-Fang Weng, Lironne Wein, Maria Joao Silva, Andjelija Zivanovic Bujak, Miriam M Yeung, Sarah Ftouni, Rodney J Hicks, Prudence A Francis, Chee Khoon Lee, Sarah-Jane Dawson, Sherene Loi

Journal article  |  2022  |  CANCER DISCOVERY

UNLABELLED: There is limited knowledge on the benefit of the α-subunit-specific PI3K inhibitor alpelisib in later lines of therapy..

Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions

Steven David, Jennifer Tan, Shankar Siva, Lama Karroum, Peter Savas, Sherene Loi

Journal article  |  2022  |  BIOMEDICINES

The role of radiotherapy and immunotherapy with immune checkpoint inhibitors (ICI) is of emerging interest in many solid tumours, ..

Abstract PD10-02: A randomised phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients with advanced triple negative breast cancer (AZTEC trial)

Steven David, Peter Savas, Shankar Siva, Michelle White, Michael W Neeson, Shane White, Gavin Marx, Robyn Cheuk, Michelle Grogan, Maria Farrell, Jessica Foudoulis, Annette Dempsey, Paul J Neeson, Mathias Bressel, Sherene Loi

Conference Proceedings  |  2022  |  Cancer Research

Abstract A randomised phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiothe..

Abstract P1-18-14: Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: A phase II study

Peter Savas, Louisa Lisa Lo, Stephen James Luen, Elizabeth Fay Blackley, Courtney Templeton van Geelen, Yi-An Ko, Kate Moodie, Jason William Callahan, Chen-Fang Weng, Andjelija Zivanovic Bujak, Miriam Manning Yeung, Sarah Ftouni, Prudence Anne Francis, Sarah-Jane Dawson, Sherene Loi

Conference Proceedings  |  2022  |  Cancer Research

Abstract Background: The PI3Kα subunit specific inhibitor alpelisib in combination with fulvestrant is approved in ..

Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers

Peter Savas, Roberto Salgado, Sherene Loi

Journal article  |  2021  |  BREAST CANCER RESEARCH AND TREATMENT

Here we will provide an immune-focussed overview of biomarkers in early and advanced stage breast cancer. It should be noted from ..

Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Jennifer Mooi, Fiona Chionh, Peter Savas, Jessica Da Gama Duarte, Geoffrey Chong, Stephen Brown, Rachel Wong, Timothy J Price, Alysson Wann, Effie Skrinos, John M Mariadason, Niall C Tebbutt

Journal article  |  2021  |  CLINICAL CANCER RESEARCH

PURPOSE: To assess the efficacy and safety of dual antiangiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in ..

Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)

Peter Schmid, Delphine Loirat, Peter Savas, Enrique Espinosa, Valentina Boni, Antoine Italiano, Shane White, Victor Laliman, Geraldine Strasser, Kui Lin, Karen Cheng, Aruna Mani, Matthew Wongchenko, Marie-Paule Sablin, Kalpit Shah

Conference Proceedings  |  2021  |  CANCER RESEARCH

A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours

Sunit Sarkar, Ben Tran, Lisa Horvath, Michael Lam, Peter Savas, Peter Grimison, James R Whittle, James C Kuo, Nicole Signal, David Edmonds, Philip Hogg, Danny Rischin, Jayesh Desai, Anne Hamilton

Journal article  |  2021  |  CANCER CHEMOTHERAPY AND PHARMACOLOGY

PURPOSE: This phase I study was conducted to evaluate the safety and Maximum Tolerated Dose of PENAO (4-(N-(S-penicillaminylacetyl..

Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer Update for 2020

Lauren C Brown, Roberto Salgado, Stephen J Luen, Peter Savas, Sherene Loi

Journal article  |  2021  |  CANCER JOURNAL

Triple-negative breast cancer (TNBC) continues to represent an unmet need because of its significantly poorer outcomes, including ..

Pervasive chromosomal instability and karyotype order in tumour evolution

Thomas BK Watkins, Emilia L Lim, Marina Petkovic, Sergi Elizalde, Nicolai J Birkbak, Gareth A Wilson, David A Moore, Eva Gronroos, Andrew Rowan, Sally M Dewhurst, Jonas Demeulemeester, Stefan C Dentro, Stuart Horswell, Lewis Au, Kerstin Haase, Mickael Escudero, Rachel Rosenthal, Maise Al Bakir, Hang Xu, Kevin Litchfield, et al.

Journal article  |  2020  |  NATURE

Chromosomal instability in cancer consists of dynamic changes to the number and structure of chromosomes1,2. The resulting diversi..